MarketInOut Stock Screener Log In | Sign Up

Avalo Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Avalo Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization384.53 mln
Float48.06 mln
Earnings Date11/05/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-6.14
Highly reliable

1-Year Forecast

36.60
Transformational upside

Relative Strength

2 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

Pre-Tax Margin

-169,766%
Severely loss-making

Business Description

Founded in 2011 and based in Rockville, Maryland, Avalo Therapeutics is a U.S. biotech company working to bring new treatments to patients whose immune systems cause harmful inflammation. The company's most advanced drug candidate, AVTX-009, is currently being tested in a mid-stage clinical trial targeting a protein linked to inflammatory conditions. Previously operating under the name Cerecor Inc., the company rebranded as Avalo Therapeutics in August 2021.

Key Fundamentals

EPS-4.31
ROE-63.01
RPS0.00
ROIC-314
ROA-52.25
EBITDA, mln-100
EV / EBITDA2.08
EV / EBIT2.08
Revenue, mln0.06

Quote Details

Last 7.17
Change -0.27 (-3.63%)
Open 7.38
Volume 1,534,516
Turnover 11,002,480
Average Volume 2,709,728

Financial Ratios

Pre-Tax Profit Margin-169,766
Leverage Ratio1.09
Current Ratio19.31
Price / Book0.80
Price / Tangible Book0.82
Debt / Equity0.01
Price / Sales2,250

Financial Strength

Altman Z-Score3.99
Piotroski F-Score 3 / 9
Beneish M-Score-6.14
1-Year Target Price36.60
Short Ratio10.66
Short % of Float22.34

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.46% 85 / 100   
1 Month -52.04% 3 / 100   
2 Months -63.23% 5 / 100   
6 Months -47.7% 14 / 100   
1 Year -60.25% 15 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog